Sierra Leone

April 19, 2016

Results of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 have been published today (April 19) in PLOS Medicine. Using a novel approach designed to get rapid indications of a drug's effectiveness, the trial showed that at the dose given the drug did not improve survival compared to historic controls.

TKM-130803 interferes with the production of two essential Ebola virus proteins and has been shown to improve survival when given to monkeys experimentally infected with Ebola virus. Scientists from the University of Oxford and Sierra Leone worked with the humanitarian organisation GOAL Global, the World Health Organisation, and collaborators from a number of other institutions to test whether TKM-130803 could improve survival in adults with Ebola infection.

The researchers used a new approach to generate early evidence of effectiveness or ineffectiveness. This method can be used as a tool to screen potential therapies and determine the need for further studies (including randomised controlled trials) during an epidemic. The approach meant that the study was quickly able to reach a pre-defined point to stop the trial.

Thursday April 14, 2016

Africa Health Budget Network (AHBN) yesterday launched a new campaign dubbed #ValueOurHealth at Kona Lodge, King Street in Freetown which is a prelude to the Global launch tomorrow.
#ValueOurHealth campaign which theme is ‘open and participatory budgets lead to more and better health spending for women and children’ is calling on all governments in Sub-Saharan Africa to take urgent action to increase access to budget information and to provide more opportunity for public engagement in the budgeting process.